Helen King

The annual ASCO meeting begins at the end of the week, a conference that has often provided a tailwind for biotech and pharma names.

Biotech has been a laggard this year, gaining big in February and March but declining and trading in a choppy range since then.

Bank of America analyst Geoff Meacham identified three companies that could get a positive reception at the meeting.

Leave a Reply

Your email address will not be published. Required fields are marked *